

Special Issue

Promising Biomarkers in Liquid Biopsy of Cancer

Message from the Guest Editor

Targeted therapies have revolutionized the treatment of cancer. While these targets change during disease evolution or in response to therapy, it is extremely important to follow these alterations so that patients receive the appropriate treatment at each stage of the disease. Liquid biopsy (LB) can easily address this problem without painful interventions. LB is also an important tool for finding new therapeutic targets as well as prognostic factors for cancer patients. The main constituents of LB are circulating tumor cells (CTCs), ctDNA, exosomes, and microRNAs. Evaluation of one or more of these factors may provide useful information. Many studies have shown that specific CTC subtypes are much more important for prediction or prognosis compared to simple enumeration of total CTCs. On the other hand, the identification of specific mutations in ctDNA has also been shown to be a valuable predictive factor for specific treatments, such as EGFR targeted therapies. In this Special Issue we will focus on new biomarkers in every aspect of LB that can be used for prognosis, prediction to treatment or presenting new therapeutic targets.

Guest Editor

Dr. Galatea Kallergi
Department of Biology, University of Patras, 26504 Patras, Greece

Deadline for manuscript submissions

closed (31 January 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/81194

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)